In addition, high levels of ANXA1 expression are consistently observed in triple-negative breast cancer (TNBC), compared with other breast cancer subtypes [13–15], suggesting that it might be a promising therapeutic target in these tumours. This evidence concerns the gene ANXA1 and breast carcinoma.